Skip to main content
Top
Published in: Cancer Causes & Control 2/2020

01-02-2020 | Breast Disease | Original Paper

Sexual orientation and benign breast disease in a cohort of U.S. women

Authors: Brittany M. Charlton, Leslie V. Farland, Ulrike Boehmer, Rulla M. Tamimi, Laura C. Collins, Nicole A. VanKim, Elizabeth R. Bertone-Johnson, Jennifer Potter, Vishnudas Sarda, S. Bryn Austin

Published in: Cancer Causes & Control | Issue 2/2020

Login to get access

Abstract

Purpose

Several studies indicate that sexual minority (e.g., bisexual, lesbian) women may be at an increased risk for breast cancer. However, we know little about how risk factors, such as benign breast disease (BBD)—which can confer nearly a fourfold breast cancer risk increase—may vary across sexual orientation groups.

Methods

Among Nurses’ Health Study II participants followed from 1989 to 2013 (n = 99,656), we investigated whether bisexual and lesbian women were more likely than heterosexual women to have breast cancer risk factors including a BBD diagnosis (self-reported biopsy or aspiration confirmed, n = 11,021). Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI).

Results

Compared to heterosexuals, sexual minority participants more commonly reported certain breast cancer risk factors including increased alcohol intake and nulliparity. However, sexual minority participants were more likely than heterosexuals to have certain protective factors including higher body mass index and less oral contraceptive use. When evaluating age- and family history-adjusted rates of BBD diagnoses across sexual orientation groups, bisexual (HR 1.04, 95% CI [0.78, 1.38]) and lesbian (0.99 [0.81, 1.21]) women were just as likely as heterosexuals to have a BBD diagnosis. Results were similar after adjusting for other known breast cancer risk factors.

Conclusions

In this cohort of women across the U.S., sexual minorities were more likely than heterosexuals to have some breast cancer risk factors—including modifiable risk factors such as alcohol intake. Heterosexual, bisexual, and lesbian women were equally as likely to have a BBD diagnosis.
Literature
1.
go back to reference Meads C, Moore D (2013) Breast cancer in lesbians and bisexual women: systematic review of incidence, prevalence and risk studies. BMC Public Health 13:1127CrossRef Meads C, Moore D (2013) Breast cancer in lesbians and bisexual women: systematic review of incidence, prevalence and risk studies. BMC Public Health 13:1127CrossRef
8.
go back to reference Cochran S, Mays V, Bowen D et al (2001) Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. Am J Public Health 91:591–597CrossRef Cochran S, Mays V, Bowen D et al (2001) Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. Am J Public Health 91:591–597CrossRef
9.
go back to reference Valanis BG, Bowen DJ, Bassford T et al (2000) Sexual orientation and health: comparisons in the women’s health initiative sample. Arch Fam Med 9:843–853CrossRef Valanis BG, Bowen DJ, Bassford T et al (2000) Sexual orientation and health: comparisons in the women’s health initiative sample. Arch Fam Med 9:843–853CrossRef
11.
go back to reference Rankow EJ (1995) Breast and cervical cancer among lesbians. Womens Health Issues 5:123–129CrossRef Rankow EJ (1995) Breast and cervical cancer among lesbians. Womens Health Issues 5:123–129CrossRef
13.
go back to reference Dyrstad SW, Yan Y, Fowler AM, Colditz GA (2015) Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 149:569–575CrossRef Dyrstad SW, Yan Y, Fowler AM, Colditz GA (2015) Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 149:569–575CrossRef
14.
go back to reference Marshal MP, Friedman MS, Stall R et al (2008) Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction 103:546–556CrossRef Marshal MP, Friedman MS, Stall R et al (2008) Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction 103:546–556CrossRef
22.
go back to reference Lunn M, McNeil D (1995) Applying cox regression to competing risks. Biometrics 51:524–532CrossRef Lunn M, McNeil D (1995) Applying cox regression to competing risks. Biometrics 51:524–532CrossRef
23.
go back to reference Graham R, Berkowitz B, Blum R, Bockting W, Bradford J, de Vries B, Makadon H (2011) The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Institute of Medicine, Washington (DC) Graham R, Berkowitz B, Blum R, Bockting W, Bradford J, de Vries B, Makadon H (2011) The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Institute of Medicine, Washington (DC)
24.
go back to reference Solarz AL (1999) Lesbian health: current assessment and directions for the future. Institute of Medicine (US) Committee on Lesbian Health Research Priorities, Washington (DC). Solarz AL (1999) Lesbian health: current assessment and directions for the future. Institute of Medicine (US) Committee on Lesbian Health Research Priorities, Washington (DC).
Metadata
Title
Sexual orientation and benign breast disease in a cohort of U.S. women
Authors
Brittany M. Charlton
Leslie V. Farland
Ulrike Boehmer
Rulla M. Tamimi
Laura C. Collins
Nicole A. VanKim
Elizabeth R. Bertone-Johnson
Jennifer Potter
Vishnudas Sarda
S. Bryn Austin
Publication date
01-02-2020
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 2/2020
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01258-z

Other articles of this Issue 2/2020

Cancer Causes & Control 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine